{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:31:57Z","timestamp":1777350717927,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005923","name":"International Association for the Study of Lung Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.lungcan.2020.12.028","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T14:40:37Z","timestamp":1609425637000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8820-3205","authenticated-orcid":false,"given":"Puey Ling","family":"Chia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagun","family":"Parakh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prudence","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7319-8546","authenticated-orcid":false,"given":"Hui K","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3304-1207","authenticated-orcid":false,"given":"Khashayer","family":"Asadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-1844","authenticated-orcid":false,"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmel","family":"Murone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzena","family":"Walkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibhusal","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona E","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2020.12.028_bib0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev-publhealth-031811-124704","article-title":"The worldwide pandemic of asbestos-related diseases","volume":"34","author":"Stayner","year":"2013","journal-title":"Annu. Rev. Public Health"},{"issue":"5","key":"10.1016\/j.lungcan.2020.12.028_bib0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5694\/mja11.10125","article-title":"Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation","volume":"195","author":"Olsen","year":"2011","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.lungcan.2020.12.028_bib0015","series-title":"Third Wave of Asbestos Disease","author":"Landrigan","year":"1991"},{"key":"10.1016\/j.lungcan.2020.12.028_bib0020","series-title":"Oncologic Therapies","author":"Vokes","year":"2002"},{"issue":"7","key":"10.1016\/j.lungcan.2020.12.028_bib0025","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ctrv.2011.01.001","article-title":"Advances in the biology of malignant pleural mesothelioma","volume":"37","author":"Zucali","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2020.12.028_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/1878-0261.12651","article-title":"Genetic alterations of malignant pleural mesothelioma: association to tumor heterogeneity and overall survival","author":"Quetel","year":"2020","journal-title":"Mol. Oncol."},{"issue":"Suppl 4","key":"10.1016\/j.lungcan.2020.12.028_bib0035","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.lungcan.2020.12.028_bib0040","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: at last, cancer therapy meets systems biology","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"Suppl 5","key":"10.1016\/j.lungcan.2020.12.028_bib0045","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1289\/ehp.97105s51073","article-title":"Mechanisms of fiber-induced genotoxicity","volume":"105","author":"Jaurand","year":"1997","journal-title":"Environ. Health Perspect."},{"issue":"2","key":"10.1016\/j.lungcan.2020.12.028_bib0050","first-page":"181","article-title":"Activation of the PI3K-AKT pathway in human malignant mesothelioma cells","volume":"2","author":"Suzuki","year":"2009","journal-title":"Mol. Med. Rep."},{"issue":"3","key":"10.1016\/j.lungcan.2020.12.028_bib0055","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.onc.1207163","article-title":"Src-dependent ERK5 and Src\/EGFR-dependent ERK1\/2 activation is required for cell proliferation by asbestos","volume":"23","author":"Scapoli","year":"2004","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.lungcan.2020.12.028_bib0060","first-page":"333","article-title":"Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers","volume":"152","author":"Pache","year":"1998","journal-title":"Am. J. Pathol."},{"issue":"4 Pt 1","key":"10.1016\/j.lungcan.2020.12.028_bib0065","first-page":"L684","article-title":"Asbestos-induced phosphorylation of epidermal growth factor receptor is linked to c-fos and apoptosis","volume":"277","author":"Zanella","year":"1999","journal-title":"Am. J. Physiol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.12.028_bib0070","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2005.10.016","article-title":"EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations","volume":"51","author":"Destro","year":"2006","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2020.12.028_bib0075","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00432-008-0384-4","article-title":"Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma","volume":"134","author":"Okuda","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2020.12.028_bib0080","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2020.12.028_bib0085","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2010.11.004","article-title":"Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?","volume":"37","author":"Agarwal","year":"2011","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.lungcan.2020.12.028_bib0090","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/jso.21901","article-title":"Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations","volume":"104","author":"Rena","year":"2011","journal-title":"J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2020.12.028_bib0095","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.lungcan.2006.08.012","article-title":"EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma","volume":"54","author":"Edwards","year":"2006","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2020.12.028_bib0100","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/bjc.1990.207","article-title":"Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody","volume":"61","author":"Dazzi","year":"1990","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2020.12.028_bib0105","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/jclinpath-2011-200631","article-title":"Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma","volume":"65","author":"Enomoto","year":"2012","journal-title":"J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.lungcan.2020.12.028_bib0110","article-title":"EGFR expression and gene copy number in malignant pleural mesothelioma in Turkey","volume":"22","author":"Onder","year":"2012","journal-title":"Int. J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2020.12.028_bib0115","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jtho.2016.03.001","article-title":"EGFR status in mesothelioma: possible implications for the efficacy of Anti-EGFR and Anti-MET therapies","volume":"11","author":"Salvi","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2020.12.028_bib0120","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/0008-5472.CAN-11-3898","article-title":"Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy","volume":"72","author":"Gan","year":"2012","journal-title":"Cancer Res."},{"issue":"29","key":"10.1016\/j.lungcan.2020.12.028_bib0125","doi-asserted-by":"crossref","first-page":"30375","DOI":"10.1074\/jbc.M401218200","article-title":"Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor","volume":"279","author":"Johns","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.lungcan.2020.12.028_bib0130","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/1535-7163.MCT-14-0820","article-title":"Characterization of ABT-806, a humanized tumor-specific Anti-EGFR monoclonal antibody","volume":"14","author":"Reilly","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"14","key":"10.1016\/j.lungcan.2020.12.028_bib0135","first-page":"5355","article-title":"Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR","volume":"61","author":"Luwor","year":"2001","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2020.12.028_bib0140","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/17425247.2019.1598374","article-title":"Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma","volume":"16","author":"Chia","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"issue":"7","key":"10.1016\/j.lungcan.2020.12.028_bib0145","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.pathol.2016.08.003","article-title":"Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma","volume":"48","author":"Thapa","year":"2016","journal-title":"Pathology"},{"issue":"10","key":"10.1016\/j.lungcan.2020.12.028_bib0150","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.jtho.2018.07.015","article-title":"Mismatch repair protein defects and microsatellite instability in malignant pleural mesothelioma","volume":"13","author":"Arulananda","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2020.12.028_bib0155","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/jcp.2009.066548","article-title":"EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer","volume":"62","author":"Varella-Garcia","year":"2009","journal-title":"J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.lungcan.2020.12.028_bib0160","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2020.12.028_bib0165","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1073\/pnas.232686499","article-title":"A monoclonal antibody recognizing human cancers with amplification\/overexpression of the human epidermal growth factor receptor","volume":"100","author":"Jungbluth","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.lungcan.2020.12.028_bib0170","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/ijc.21454","article-title":"EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus","volume":"118","author":"Hanawa","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2020.12.028_bib0175","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/jclinpath-2011-200631","article-title":"Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma","volume":"65","author":"Enomoto","year":"2012","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.lungcan.2020.12.028_bib0180","series-title":"AACR Annual Meeting 2017","article-title":"Abstract 25: effect of nimotuzumab on malignant pleural mesothelioma cell lines","year":"2017"},{"issue":"10","key":"10.1016\/j.lungcan.2020.12.028_bib0185","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bcp.2011.07.073","article-title":"Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1\/2 as antitumor targets","volume":"82","author":"Barbieri","year":"2011","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.lungcan.2020.12.028_bib0190","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1593\/neo.04271","article-title":"Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors","volume":"6","author":"Liu","year":"2004","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.lungcan.2020.12.028_bib0195","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3892\/ijo.2012.1607","article-title":"Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma","volume":"41","author":"Kurai","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2020.12.028_bib0200","first-page":"5242","article-title":"Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma","volume":"62","author":"J\u00e4nne","year":"2002","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2020.12.028_bib0205","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2020.12.028_bib0210","series-title":"Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma (NCT01592383)","year":"2017"},{"key":"10.1016\/j.lungcan.2020.12.028_bib0215","unstructured":"University Hospital G. Study of Cetuximab Combined With Cisplatin or Carboplatin\/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma (MesoMab NCT00996567) [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00996567."},{"issue":"5","key":"10.1016\/j.lungcan.2020.12.028_bib0220","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JTO.0b013e318215a07d","article-title":"Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy","volume":"6","author":"Brevet","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2020.12.028_bib0225","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1021\/bc800289a","article-title":"Novel peptide linkers for highly potent antibody\u2212 auristatin conjugate","volume":"19","author":"Doronina","year":"2008","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.lungcan.2020.12.028_bib0230","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/1535-7163.MCT-17-0710","article-title":"Characterization of ABBV-221, a tumor-selective EGFR-targeting antibody drug conjugate","volume":"17","author":"Phillips","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2020.12.028_bib0235","article-title":"ABT-806-derived antibody-drug conjugates (ADCs) inhibit growth of malignant mesothelioma in vivo","author":"Chia","year":"2018","journal-title":"AACR"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022030756X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022030756X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:45:00Z","timestamp":1759236300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022030756X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":47,"alternative-id":["S016950022030756X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.12.028","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}